Addiction Treatment Levels of Care Explained

Most people searching for addiction treatment are handed a list of facilities and left to guess which one matches their situation. The more useful frame is not which program but which level of care — a structural question that professionals answer before any specific provider enters the conversation.

Levels of care describe how much medical and clinical intensity a person needs, and how much structure. Get that determination right and the choice of provider narrows considerably. Get it wrong in either direction — too little support, or a residential admission for someone who did not need one — and the odds of the episode working drop.

What are the levels of care in addiction treatment?

The most widely used framework in the United States comes from the American Society of Addiction Medicine, whose criteria organise care into a graded continuum. The broad tiers look like this:

Early intervention covers assessment and education for people whose use is concerning but does not yet meet criteria for a substance use disorder. It is brief and often delivered in primary care.

Outpatient treatment means scheduled individual or group sessions — commonly a few hours per week — while the person continues to live at home and usually keeps working. Medication for addiction treatment, such as buprenorphine or naltrexone, is frequently prescribed at this level.

Intensive outpatient and partial hospitalisation sit in the middle. Intensive outpatient programmes typically run several hours a day, several days a week. Partial hospitalisation is more intensive still, often approaching a full weekday schedule, with medical and psychiatric oversight available but the person sleeping at home.

Residential and inpatient care provides a 24-hour therapeutic environment. ASAM subdivides this tier by how much clinical monitoring is available, ranging from low-intensity residential settings staffed for support to medically monitored intensive inpatient care with nursing and physician coverage.

Medically managed intensive inpatient care is the top of the continuum: an acute hospital-level setting for people with unstable medical or psychiatric conditions alongside their substance use.

Withdrawal management — what most people call detox — is not a separate tier so much as a service that can be delivered at several of these levels depending on medical risk.

How is the right level of care decided?

A competent assessment does not ask what a person wants; it evaluates risk across several dimensions simultaneously. The ASAM framework organises these into six: acute intoxication and withdrawal potential, biomedical conditions, psychiatric and cognitive conditions, readiness to change, risk of relapse or continued use, and the recovery environment.

That last dimension is the one people underestimate. Someone with moderate physiological dependence but a stable home, employment, and a supportive partner may do well in an intensive outpatient programme. Someone with identical use patterns who is living with active users, unhoused, or isolated may need residential care for reasons that have nothing to do with the substance itself.

A provider who recommends the same level of care to nearly everyone who calls is not assessing — they are selling. This is the single most useful signal available to a family during the first phone call. Ask what the assessment covers and how often the recommendation differs from the program the provider happens to offer.

The comprehensive overview of addiction treatment options covers how these determinations interact with specific substances, since withdrawal risk differs sharply between alcohol, benzodiazepines, and opioids.

Where does withdrawal management fit?

Detox is a starting point, not a treatment. This distinction gets lost constantly, and it accounts for a great deal of avoidable relapse — someone completes a five-day medical detox, is discharged with no next step, and returns to the same environment with a reduced physiological tolerance and unchanged circumstances.

Medical risk during withdrawal varies enormously by substance. Alcohol and benzodiazepine withdrawal can produce seizures and delirium and may require inpatient medical management. Opioid withdrawal is profoundly uncomfortable but is rarely life-threatening in an otherwise healthy adult, though it becomes dangerous in the context of pregnancy, cardiac disease, or severe dehydration. Stimulant withdrawal is primarily psychiatric, with depression and suicidality as the main concerns.

Accelerated approaches exist as well. Rapid detox protocols compress opioid withdrawal using antagonist medications, sometimes under sedation or anaesthesia — an approach with meaningful medical risks and a contested evidence base, which is worth understanding in detail before considering it.

Whatever the method, the question that determines the outcome is the same: what happens on day six? A withdrawal management episode that is not explicitly linked to a next level of care should be treated as an incomplete plan.

What does moving through the continuum look like?

The continuum is meant to be traversed, not selected from once. A typical arc might begin with medically monitored withdrawal management, step down to residential care for several weeks, step down again to partial hospitalisation, then to intensive outpatient, then to weekly outpatient therapy with ongoing medication — each transition reducing structure as stability increases.

Two things commonly go wrong.

The first is a discharge cliff: someone completes a residential stay and steps directly to nothing. The drop in structure is abrupt at exactly the point when confidence is high and tolerance is low. Continuing care planning should begin in the first week of any residential admission, not the last.

The second is a failure to step back up. Returning to a higher level of care after a lapse is a normal and clinically appropriate response, not a verdict. Programmes that frame it as failure discourage the people who most need to come back.

Substance use disorders behave like other chronic conditions in this respect. Care is adjusted over time rather than completed. Long-term monitoring and the ability to re-intensify support are better predictors of sustained recovery than the length of any single episode.

Medication is the other thread that should run continuously through the continuum rather than stopping at discharge. For opioid use disorder, buprenorphine and methadone are the interventions with the strongest evidence for reducing overdose death, and naltrexone has a role for both opioid and alcohol use disorder. Acamprosate and disulfiram are options for alcohol. A residential admission that starts someone on buprenorphine and then discharges them without an established prescriber has created a cliff in the one dimension that most affects mortality. Ask who will prescribe in week five, and confirm the appointment exists before discharge rather than after.

Where do alternatives like ibogaine fit in this framework?

Ibogaine does not map neatly onto the ASAM continuum, and it is worth being precise about why.

The claim made for ibogaine is that a single supervised administration can substantially reduce acute opioid withdrawal and diminish craving for a period afterward. Observational studies and case series describe this effect; controlled trials remain limited. Where ibogaine plausibly functions is as a withdrawal management and craving-interruption intervention — roughly the position occupied by medically monitored detox — rather than as a replacement for the therapeutic and continuing-care tiers above it.

That framing matters because it clarifies what ibogaine does not do. It does not build behavioural skills, repair a recovery environment, treat co-occurring psychiatric conditions, or provide the ongoing monitoring that distinguishes durable recovery from a good first month. People who report lasting benefit almost uniformly describe substantial work afterward.

Ibogaine also carries cardiac risk that conventional withdrawal management does not. It prolongs the QT interval and has been associated with fatal arrhythmias, which is why electrocardiography, electrolyte correction, and continuous cardiac monitoring are non-negotiable, and why it is unavailable as an approved treatment in the United States. Our comparison of how ibogaine differs from traditional rehab examines these trade-offs against the conventional continuum in detail.

How do you compare programs at the same level of care?

Once the level is settled, a handful of questions separate serious providers from the rest.

Ask who conducts the assessment and what their credentials are. Ask whether medication for addiction treatment is available on site or whether the program is abstinence-only — a significant difference for opioid use disorder, where buprenorphine and methadone have the strongest evidence for reducing mortality. Ask how co-occurring psychiatric conditions are handled, because roughly half of people with a substance use disorder have another diagnosis. Ask what the continuing care plan looks like and who owns it after discharge.

Ask about staffing ratios overnight and on weekends, which is when problems surface. Ask what the program does when someone lapses during treatment.

Ask, too, about the things that are easy to verify and rarely volunteered. Is the facility licensed by the state, and at what level? Are the clinicians delivering therapy licensed independently or working under supervision? Is the medical director on site or a name on a wall? Does the program accept insurance, and if not, what does the total cost include — because programs quoting a weekly rate often exclude medications, laboratory work, and psychiatric consultation, and the gap between the quoted figure and the final invoice can be substantial.

Finally, be sceptical of success-rate claims. There is no standard definition, no independent verification, and no requirement to publish. A provider quoting a high figure without specifying how it was measured, over what interval, and with what follow-up rate is quoting marketing, not data.

Understanding levels of care turns an overwhelming search into a sequence of answerable questions. If you are trying to work out where you or a family member fits on this continuum — and whether conventional care, an alternative approach, or a combination makes sense — the Ibogaine Treatment Guide covers each option with the evidence and the risks laid out plainly. Start with an honest assessment of the recovery environment, because that is the factor most likely to decide which level of addiction treatment you actually need.

---

This article is for education and is not medical advice. Substance withdrawal can be medically dangerous and should be managed by qualified clinicians. If you are in immediate danger, contact emergency services. In the United States, the SAMHSA National Helpline is available at 1-800-662-4357, and the 988 Suicide and Crisis Lifeline can be reached by calling or texting 988.